<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Lyomark</title>
	<atom:link href="https://lyomark.com/en/feed/" rel="self" type="application/rss+xml" />
	<link>https://lyomark.com/en</link>
	<description>New products for indications in neonatology, gastroenterology and oncology</description>
	<lastBuildDate>Wed, 27 May 2026 08:27:32 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updateperiod>
	per hour	</sy:updateperiod>
	<sy:updatefrequency>
	1	</sy:updatefrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://lyomark.com/site/wp-content/uploads/logo.svg</url>
	<title>Lyomark</title>
	<link>https://lyomark.com/en</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Change in Management at Lyomark Pharma GmbH and Bendalis GmbH</title>
		<link>https://lyomark.com/en/changes-in-management-at-lyomark-pharma-gmbh-and-bendalis-gmbh-2/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Mon, 11 Apr 2022 08:33:11 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[Neuigkeiten Lyomark]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=3101</guid>

					<description><![CDATA[Oberhaching, April 2022

Dear Sir or Madam,

Today we are informing you about a personnel change at Lyomark Pharma GmbH and Bendalis GmbH. Mr Parvany will be leaving the companies on 31 March 2022. Mr Parvany has been active in both companies since 2012, initially as Head of Sales and Marketing and as Managing Director since 2019. […]]]></description>
		
		
		
			</item>
		<item>
		<title>Change in Management at Lyomark Pharma GmbH and Bendalis GmbH</title>
		<link>https://lyomark.com/en/changes-in-management-at-lyomark-pharma-gmbh-and-bendalis-gmbh/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Tue, 21 Sep 2021 14:49:12 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[Neuigkeiten Lyomark]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2923</guid>

					<description><![CDATA[Oberhaching, 21 September 2021 Dear Sir or Madam, Today we are informing you about a change in personnel at Lyomark Pharma GmbH and Bendalis GmbH. Mr Malocho will be leaving the companies on 30.09.2021. Mr Malocho has been employed by both companies since 2006, initially as Head of Supply Chain and since 2014 as Managing Director. We would like […]]]></description>
		
		
		
			</item>
		<item>
		<title>Lung surfactant: A potential candidate for influencing inflammatory responses</title>
		<link>https://lyomark.com/en/lung-surfactant-a-potential-candidate-for-influencing-inflammatory-responses/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Wed, 17 Feb 2021 14:31:14 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Alveofact]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[Natürliches Surfactant]]></category>
		<category><![CDATA[surfactant]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2870</guid>

					<description><![CDATA[The importance of a healthy and well-functioning immune system is perhaps most evident in times of a global pandemic. Pathogenic microorganisms often find their way into our bodies through the lungs, which requires an initial, appropriately developed immune response. As neutrophils are the first immune cells to reach the site of infection, they play an important role in […]]]></description>
		
		
		
			</item>
		<item>
		<title>Surfactant – helpful in the treatment of COVID-associated pneumonia?</title>
		<link>https://lyomark.com/en/surfactant-useful-in-the-treatment-of-covid-associated-pneumonia/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Tue, 15 Dec 2020 08:51:19 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Alveofact]]></category>
		<category><![CDATA[Covid-assoziierter Pneumonie]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[Natürliches Surfactant]]></category>
		<category><![CDATA[surfactant]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2816</guid>

					<description><![CDATA[SARS-CoV-2 can lead to a severe form of pneumonia which, under certain circumstances, can trigger acute lung failure (ARDS, „Acute Respiratory Distress Syndrome“). This is an „excessive“ inflammatory response: inflammatory cells and fluid build up in the lungs. This mechanically hinders breathing on the one hand and destroys the anti-inflammatory fluid, the body's own protective film („surfactant“), in the alveoli on the other, which […]]]></description>
		
		
		
			</item>
		<item>
		<title>Feasibility study on Neofact® published: The innovative LISA application aid Neofact® is successful.</title>
		<link>https://lyomark.com/en/neofact-feasibility-study-published/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Fri, 09 Oct 2020 13:55:38 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Alveofact]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[surfactant]]></category>
		<category><![CDATA[wundheilung]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2739</guid>

					<description><![CDATA[In the clinical study conducted at the University Hospital Tübingen, 20 premature infants (gestational age ≥ 26 + 0/7 weeks) were administered the surfactant Alveofact® (45 mg/ml; Lyomark Pharma, Oberhaching, Germany) with the new LISA application aid Neofact®. The aim of Neofact® was to enable a simple and gentle procedure for surfactant administration, which could be done without the use of […]]]></description>
		
		
		
			</item>
		<item>
		<title>Surfactant – the new preparation for promoting wound healing?</title>
		<link>https://lyomark.com/en/lyomark-pharma-alveofact-wound-healing/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Fri, 17 Apr 2020 07:27:11 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Alveofact]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[surfactant]]></category>
		<category><![CDATA[wundheilung]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2635</guid>

					<description><![CDATA[Skin wound healing disorders are characterised by persistent inflammation, chronic non-healing ulcers or excessive scarring with an ongoing inflammatory response. Surgical removal of diseased tissue, followed by plastic-reconstructive wound closure or long-term treatment with various wound dressings, currently represents the standard therapy. The social impact of aberrant wound healing, in addition to high healthcare costs and economic consequences, manifests itself […]]]></description>
		
		
		
			</item>
		<item>
		<title>Thank you for visiting CPhI Frankfurt</title>
		<link>https://lyomark.com/en/meet-us-at-cphi-in-madrid-2-2/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Wed, 13 Nov 2019 11:13:18 +0000</pubDate>
				<category><![CDATA[Veranstaltungen]]></category>
		<category><![CDATA[cphi]]></category>
		<category><![CDATA[lyomark]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2587</guid>

					<description><![CDATA[We would like to thank all our partners and interested parties for the many stimulating discussions during CPhI in Frankfurt. We hope that the days in Frankfurt were as successful for you as they were for us. We look forward to seeing you all again next year from 13th – 15th October in Milan. Your Lyomark Pharma Team]]></description>
		
		
		
			</item>
		<item>
		<title>Meet us at CPhI in Frankfurt</title>
		<link>https://lyomark.com/en/meet-us-at-cphi-in-madrid-2/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Fri, 06 Sep 2019 14:15:36 +0000</pubDate>
				<category><![CDATA[Veranstaltungen]]></category>
		<category><![CDATA[cphi]]></category>
		<category><![CDATA[lyomark cphi]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2564</guid>

					<description><![CDATA[This year, Lyomark Pharma will once again be present with its own stand at the CPhI trade fair from 5th to 7th November in Frankfurt. We would be delighted to welcome you to our stand 92F23 in Hall 9.2. Your Lyomark Pharma Team]]></description>
		
		
		
			</item>
		<item>
		<title>Meet us at the GNPI Congress 2019 in Leipzig and try NEOFACT®</title>
		<link>https://lyomark.com/en/meet-us-at-the-gnpi-congress-2019-in-leipzig/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Fri, 17 May 2019 07:45:56 +0000</pubDate>
				<category><![CDATA[Veranstaltungen]]></category>
		<category><![CDATA[GNPI 2019]]></category>
		<category><![CDATA[lyomark]]></category>
		<category><![CDATA[Lyomark Pharma]]></category>
		<category><![CDATA[Neofact]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2515</guid>

					<description><![CDATA[From 23 to 25 May 2019, we will be presenting our products at the GNPI Congress in Leipzig. Visit us at Stand 2 and test the innovative application aid NEOFACT® on the premature baby simulator. We look forward to seeing you!]]></description>
		
		
		
			</item>
		<item>
		<title>NEOFACT® – The innovative application aid for surfactant instillation</title>
		<link>https://lyomark.com/en/neofact-the-innovative-application-aid-for-surfactant-instillation/</link>
		
		<dc:creator><![CDATA[Dirk Hütten]]></dc:creator>
		<pubDate>Tue, 02 Apr 2019 13:46:26 +0000</pubDate>
				<category><![CDATA[Aktuelles]]></category>
		<category><![CDATA[Alveofact]]></category>
		<category><![CDATA[lyomark]]></category>
		<category><![CDATA[Neofact]]></category>
		<category><![CDATA[Surfactant Applikation]]></category>
		<guid ispermalink="false">https://www.lyomark.com/?p=2471</guid>

					<description><![CDATA[Lyomark Pharma remains on a growth trajectory and is launching its own application aid for surfactant instillation onto the market with NEOFACT®. NEOFACT® was developed in practice to support surfactant therapy. Thanks to NEOFACT®, surfactant administration can be carried out easily and without a Magill forceps. Find out more about NEOFACT® here.]]></description>
		
		
		
			</item>
	</channel>
</rss>